Disclosure Policy

1. Basic Policy on Information Disclosure

Noile-Immune Biotech, Inc (hereinafter "the Company") is committed to disclosing information promptly and appropriately to shareholders, investors, and all other stakeholders in a transparent, fair, and continuous manner.

We will disclose information in accordance with the disclosure system of corporate affairs stipulated by the Financial Instruments and Exchange Act and the "Rules on Timely Disclosure of Company Information by Issuers of Listed Securities" (hereinafter "Timely Disclosure Rules") established by the Tokyo Stock Exchange. In addition to the important information set forth in the Timely Disclosure Rules, we shall disclose information that is deemed to have a substantive impact on investment decisions and/or to be useful in enhancing understanding of the Company in a fair and timely manner.

2. Prevention of Insider Trading

The Company has set forth internal rules for the appropriate management of important corporate information to enforce fair disclosure and prevent insider trading while promoting a thorough understanding and awareness of these rules across the entire Company.

3. Information Disclosure Methods

The Company will disclose information in accordance with the Timely Disclosure Rules via the Timely Disclosure Network (TDnet). Information disclosed on TDnet will be promptly posted on the Company's website. In addition, the Company will voluntarily disclose information deemed beneficial to stakeholders, even if such information is not subject to the Timely Disclosure Rules.

4. Handling of Financial Results Forecasts and Future Information

In addition to the financial results forecasts mentioned in the Financial Results, we may also provide other forward-looking statements. News releases, documents issued by the Company, contents of the Company's website, and questions and answers provided at financial results briefings, etc., may include current plans, future outlooks, views, strategies, and other information. Such information is made on the grounds of what the management believes to be reasonable based on the information available at the time of preparation and involves risks and uncertainties. Please be aware that various factors could materially cause actual financial results to differ from those stated in forward-looking statements.

5. Quiet Period

To ensure fairness of disclosure and prevent leaks of financial information, the Company has defined a quiet period from the end of the fiscal year and each quarter to the date of announcement of financial results, during which the Company will refrain from responding to inquiries or making comments regarding its financial results. However, if a discrepancy from the financial results forecast is realized during the quiet period, information will be disclosed appropriately and promptly in accordance with the Timely Disclosure Rules.